Last reviewed · How we verify
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.
Details
| Lead sponsor | Tarian Pharma |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | Mon Jan 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- EGFR Inhibitor-associated Rash
Interventions
- Brimonidine tartrate Gel
- Placebo gel (no Brimonidine tartrate)
Countries
France